Table 1 Baseline cohort characteristics
|  | Total (N = 3426) | Bevacizumab plus paclitaxel (n = 2127) | Paclitaxel (n = 1299) |
|---|---|---|---|
Mean (SD) age, years | 57.4 (12.4) | 54.2 (11.2) | 62.7 (12.5) |
Female, n (%) | 3391 (99.0) | 2110 (99.2) | 1281 (98.6) |
Mean (SD) number of metastatic sites | 2.1 (1.2) | 2.0 (1.1) | 2.2 (1.3) |
De novo MBC, n (%) | 663 (19.4) | 347 (16.3) | 316 (24.3) |
Mean (SD) time (months) between initial diagnosis and metastatic diagnosis | 63.6 (71.3) | 61.2 (65.7) | 67.6 (79.4) |
Median time (months) between initial diagnosis and metastatic diagnosis | 38.9 | 38.6 | 40.9 |
ER status | |||
 Negative, n (%) | 1042 (30.5%) | 665 (31.4%) | 377 (29.1%) |
 Positive, n (%) | 2371 (69.5%) | 1454 (68.6%) | 917 (70.9%) |
 Not determined, n | 13 | 8 | 5 |